John Armitage's Egerton Capital has disclosed a new significant position in Thermo Fisher Scientific (TMO), according to a recent SEC filing. The investment firm purchased 198,230 shares, valued at approximately $133.81 million as of the reporting period.
This move gives Egerton a 1.36% weight in the life sciences and diagnostics company. Investors should note that 13F filings are released quarterly and reflect positions held at the end of the previous quarter, in this case, September 30, 2026, and do not necessarily represent the firm's current holdings.